99mTc-P137 SPECT/CT in Prostate Cancer

Launched by FIRST AFFILIATED HOSPITAL XI'AN JIAOTONG UNIVERSITY · Jan 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called 99mTc-P137 SPECT/CT to improve the detection and diagnosis of prostate cancer. The goal is to see how effectively this radioactive probe can identify prostate cancer lesions, helping doctors make better decisions about treatment and patient care. Essentially, the researchers want to find out if this method can help detect cancer earlier and more accurately.

To participate in the trial, you need to be a man aged 18 or older who is suspected of having prostate cancer and is planning to undergo surgery or a biopsy. You may qualify if you have certain changes in your prostate-specific antigen (PSA) levels, have a family history of prostate cancer, or have received specific imaging scores indicating a higher risk. If you join the study, you can expect to undergo imaging tests using the 99mTc-P137 probe, and your results will be compared to standard pathology tests. This study is currently recruiting participants, and all individuals will need to give their informed consent to take part.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • patients age 18 or above;
• • highly suspicious for prostate cancer patients: 1) Serum PSA is significantly changed compared with before (PSA\<4.0ng/mL with annual change \>0.35ng/mL; or PSA \> 4.0ng/mL with annual change \> 0.75ng/mL); 2) First or second degree relatives have a history of prostate cancer; 3) Nuclear magnetic PI-RADS score ≥3 points;
• • the prostate biopsy or surgical pathology is diagnosed with prostate cancer;
• • available to provide clinical laboratory results (blood routine, biochemical and serum PSA) within one month before this study; At least two imaging examinations including CT, MRI, nuclear medicine (PET/CT or SPECT/CT), ultrasound and other imaging techniques;
• • Can complete the inspection autonomously;
• • voluntary and signed informed consent.
• Exclusion Criteria:
• • there are other malignant tumor history;
• • severe damage of liver and kidney function;
• • may not be able to obtain pathology or long-term follow-up results;
• • don't have access to relevant reference image data and clinical data;
• • difficult to cooperate.